Get the Stockscreener App
4.27
1.16%
-0.05
After Hours:
29.72
25.45
+596.02%
Relmada Therapeutics Inc stock is traded at $4.27, with a volume of 1.18M.
It is down -1.16% in the last 24 hours and up +90.62% over the past month.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
See More
Previous Close:
$4.32
Open:
$4.3
24h Volume:
1.18M
Relative Volume:
0.92
Market Cap:
$313.13M
Revenue:
-
Net Income/Loss:
$-98.79M
P/E Ratio:
-1.3058
EPS:
-3.27
Net Cash Flow:
$-51.66M
1W Performance:
+8.10%
1M Performance:
+90.62%
6M Performance:
+722.26%
1Y Performance:
+55.27%
1-Day Range:
$3.81
$4.3728
1-Week Range:
$3.7249
$5.12
52-Week Range:
$0.2404
$5.12
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.15 | 3.06B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.51 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.15 | 166.65M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.22 | 492.74M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
0.72 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-05-24 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
How risky is Relmada Therapeutics Inc. stock now2025 Key Lessons & Growth Focused Entry Reports - newser.com
How Relmada Therapeutics Inc. (4E2) stock trades in high volatilityEarnings Overview Report & Risk Controlled Daily Trade Plans - newser.com
This Stock Is Up 704% in 2025 But Has No Products to Its Name - inkl
Will Relmada Therapeutics Inc. stock sustain high P E ratiosCEO Change & Consistent Growth Equity Picks - newser.com
Is Relmada Therapeutics Inc. showing signs of accumulationQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com
Smart tools for monitoring Relmada Therapeutics Inc.’s price actionWeekly Profit Analysis & Free Daily Entry Point Trade Alerts - newser.com
Mizuho Upgrades Relmada Therapeutics (RLMD) - Nasdaq
Why Relmada Therapeutics Inc. (4E2) stock stays resilientShare Buyback & Reliable Intraday Trade Plans - newser.com
Will Relmada Therapeutics Inc. (4E2) stock outperform small cap peers - newser.com
What valuation ratios show for Relmada Therapeutics Inc. (4E2) stock - newser.com
Mizuho Upgrades RLMD to 'Outperform', Raises Price Target | RLMD Stock News - GuruFocus
Relmada Therapeutics (RLMD) Receives Upgrade with Significant Up - GuruFocus
Is Relmada Therapeutics Inc. stock ready for a breakoutOptions Play & Community Driven Trade Alerts - newser.com
Mizuho upgrades Relmada Therapeutics stock to Outperform on NDV-01 potential - Investing.com India
Mizuho Upgrades Relmada Therapeutics Inc (RLMD) to Outperform - StreetInsider
Is Relmada Therapeutics Inc. building a consolidation base2025 Performance Recap & Detailed Earnings Play Strategies - newser.com
Will Relmada Therapeutics Inc. bounce back from current supportJuly 2025 Reactions & Verified Stock Trade Ideas - newser.com
What institutional flow reveals about Relmada Therapeutics Inc.Market Trend Summary & Stepwise Swing Trade Plans - newser.com
Is Relmada Therapeutics Inc 4E2 a good long term investmentMoving Average Crossovers & Free Get High Impact Recommendations - earlytimes.in
Relmada Therapeutics Reports Q3 2025 Financial Results - MSN
Will Relmada Therapeutics Inc. stock gain from lower inflationJuly 2025 Sector Moves & Real-Time Chart Pattern Alerts - newser.com
Why Relmada Therapeutics Inc. stock is a value investor pickStop Loss & Momentum Based Trading Signals - newser.com
Can Relmada Therapeutics Inc. stock resist sector downturnsTrade Exit Summary & Weekly High Potential Alerts - newser.com
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):